Drug updated on 10/31/2024
| Dosage Form | Capsule (oral; 74.5 mg of isavuconazonium sulfate [equivalent to 40 mg of isavuconazole], 186 mg [equivalent to 100 mg of isavuconazole]); Injection (intravenous; 372 mg [equivalent to 200 mg of isavuconazole]) |
| Drug Class | Azole antifungals |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adults with invasive aspergillosis or invasive mucormycosis, by injection in adults and pediatric patients 1 year of age and older
- Indicated for the treatment of adults with invasive aspergillosis or invasive mucormycosis, through capsule administration, in adults and pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- There is no effectiveness information available in the reviewed studies.
- There is no safety information available in the reviewed studies.
- The pharmacokinetics of Isavuconazole (ISA) were assessed across specific populations, including healthy men and women, patients with invasive fungal infections and malignancies (such as those with neutropenia), and solid organ transplant recipients. Relevant covariates affecting pharmacokinetics included body mass index (BMI), total body weight, lean body mass, race, sex, and creatinine clearance, highlighting a need for further study in special populations like those with severe liver disease or on ECMO support.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Cresemba (isavuconazonium sulfate) Prescribing Information. | 2023 | Astellas Pharma US, Inc., Northbrook, IL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Population Pharmacokinetics of Isavuconazole in Adult: A Systematic Review | 2023 | Infection and Drug Resistance |